Comanche Biopharma Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway (ILAP) Steering Group for CBP-4888, an Investigational siRNA Drug Candidate for the Treatment of sFlt1-mediated Preterm Preeclampsia Comanche awarded Innovation Passport designation by the U.K. Innovative Licensing and Access Pathway Steering Group for CBP-4888 to treat preeclampasia.

Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia Comanche Biopharma closes oversubscribed $75 Million Series B financing to advance first treatment targeting a root cause of preeclampsia.